A Twist Bioscience officer told the SEC about a plan to sell $280K of Twist Bioscience shares around Oct 2, 2026. The filing says the shares were acquired as compensation.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 144 — Notice of Proposed Sale of Securities

All the details

Dates, kept separate

Planned sale date: Oct 2, 2026
Reporting period: Not applicable
Notice filed with the SEC: Oct 2, 2026

OfficerPlanned saleShares from pay

Context

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001959173-26-007246
Filed / recorded: Oct 3, 2026, 12:50 AM UTC

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Added to OQRO

Oct 7, 2026, 1:40 PM UTC

Parser

form144-v1

Data quality

Read from the record; company matched by name

Issuer

Twist Bioscience Corp

Issuer CIK

1581280

Table

Non-derivative (Table I)

Transaction date

—

Shares / units

—

Price per share

—

Shares owned after

—

Ownership form

Direct

Amendment

Around the same time

Adam Laponis (Chief Financial Officer) sold ~$1.52M of Twist Bioscience

Automatic saleFiled yesterday

Paula Green (SVP of Human Resources) sold ~$1.91M of Twist Bioscience

Automatic saleFiled yesterday

Patrick John Finn (President and COO) sold ~$4.86M of Twist Bioscience

Automatic saleFiled yesterday